Horizon 2020 Fast Track to Innovation - Lorraine Martin

1. Horizon 2020: SME Instrument Case Study
Dr Lorraine Martin
Chief Executive Officer
Co-founder
Fast Track to Innovation Seminar – 20 Jan 2015

2.  Background
 Technology & Innovation
 Roadmap to commercialisation
 Horizon 2020 – SME Instrument
 Primary considerations
 Proposal preparation & submission
 Award & grant agreement preparation
 Tangible Benefits
ProAxsis: On the fast track
Fast Track to Innovation Seminar – 20 Jan 2015

3. Technology:
Identification of an active problem
Cancer
Heart
Disease
Infection
Respiratory
Disease
Diagnostic and prognostic value:
Drug targets and Biomarkers of disease activity
Active proteases are of biomedical and
pharmaceutical importance e.g.
No tools available in the clinic or home to
monitor predictive spikes of protease activity
Fast Track to Innovation Seminar – 20 Jan 2015

4. Innovative solutions to an active problem
Protease-Tag
PROTEASE
PROTEASE
PROTEASE
PROTEASE
ProteaseTagsTM
Inactivate a specific protease
and may be used as tools to
detect and quantify the
activity of a single protease
species within a complex
biological sample
Protease-TagTM Technology:
Novel and rapid method of
detecting active protease
biomarkers
• Potential to be
incorporated into a
number of technology
platforms
• Multi-analyte
• Product pipeline

5. Roadmap to commercialisation
Proof of Concept
Awards; £100K x2
Confidence
in Concept
£100K
Commercial
Development
Award
£118K
2008
2012
2013
2009
Spin-out
Fast Track to Innovation Seminar – 20 Jan 2015

6. SMART MOLECULES
ProteaseTagsTM
“DESIGN & SYNTHESIS”
CLINICAL RESEARCH
SERVICES
ACTIVITY PROFILING
TARGET VALIDATION
CLINICAL TRIAL SUPPORT
CLINICAL/
POINT OF CARE TESTS
DEVELOPMENT OF LATERAL
FLOW DEVICES WITH
ASSOCIATED HAND-HELD
READER TECHNOLOGY
ProteaseTagTM ELISAs
KIT SALES
SERVICE PROVISION
DRUG DISCOVERY
LICENCING OPPORTUNITIES
Active markets requiring smart solutions
Constitute global sales of $7.2 billion.
Expected to double by 2020.
Rapidly growing market predicted to
be worth £20.9 billion by 2015

7. Horizon 2020 – Identify a call
 Call ID PHC 12 -2014/15: Clinical validation of
biomarkers and/or diagnostic medical devices
 Developing a test for use at point of care for a chronic
disease of significant burden across Europe and globally
 Phase 1: ENABLE: Establishment of a Neutrophil elastase
Activity home test for the Better management and treatment of
Lung Exacerbations
 Phase 2: MONITOR: Measurement Of Neutrophil elastase In the
management and Treatment Of chronic Respiratory disease

8.  Evaluate preparation time/effort vs tangible benefits
 Direct benefits:
 Phase 1: €50K (70% funding), lump sum for “deliverable” to
progress a work package
 Indirect benefits:
 PR, exposure, heightened profile
 “Deliverable” pump primes Phase 2 application: £M
(100% funding)
 Get some feedback Invest NI
Primary considerations
H2020
Advisors
Fast Track to Innovation Seminar – 20 Jan 2015

9. Fast Track to Innovation Seminar – 20 Jan 2015
Start the process – Registration
 Never too early to register with the Participants Portal
 Personal info, company info, financials
******** ********

10. Fast Track to Innovation Seminar – 20 Jan 2015
 However, some things can be left . . .
 E.g. LEAR validation
 If in doubt - ask
 Acquire PIC number
******
*
Start the process – PIC Number

11. Fast Track to Innovation Seminar – 20 Jan 2015
Proposal preparation
 Follow the instructions!
 Proposal submission document (electronic)
 Proposal in 2 parts – sections 1-3 & 4-5 (separate documents)
 Read the questions and address each point
 Be careful with jargon and clearly note abbreviations
 Consider impact - think outside the box
 European application – use Euro’s for markets and
compile as much cross-Europe data as possible
 Think carefully about task list – follow guidance
 Get feedback

12. Submission
Fast Track to Innovation Seminar – 20 Jan 2015

13. Receipt of Award – Award Letter
Fast Track to Innovation Seminar – 20 Jan 2015

14. Receipt of Award -
Evaluation Summary Report
Fast Track to Innovation Seminar – 20 Jan 2015
 Total score (out of 15.00; threshold 13.00)
 Criterion 1
 Impact (threshold 4.00/5.00)
 Criterion 2
 Excellence (threshold 4.00/5.00)
 Criterion 3
 Quality & efficiency of implementation (threshold 4.00/5.00)
 Final assessment:
 Proposal content corresponds, wholly or in part to the topic
description against which it is submitted, in the relevant work
programme part?
 Status – YES/NO

15.  All validations need to be completed
 Financial identification form
 Legal entity
 Confirmation of private company, VAT, current
appointments etc
 LEAR (Legal entity appointed representative)
 Declaration of honour
 Part B: merging of sections 1-3 and 4-5 to a
single document exc task list (inputted
separately)
Grant Agreement preparation stage
Fast Track to Innovation Seminar – 20 Jan 2015

16. Summary of Process
CALL ID
Registration
Proposal
Preparation
Submission
Grant Agreement
Preparation
Validations
Signing off
Transfer of %
funds
Receipt of award
letter
Fast Track to Innovation Seminar – 20 Jan 2015

17. Tangible benefits & PR
 Horizon 2020 SME Instrument
 €50K lump sum to support the building of resources for the
preparation of Phase 2; no detailed financial accounting
 Familiarity with the portal and process, prior to submission of
larger phase 2
 PR and company exposure
 Press releases
 Twitter
Fast Track to Innovation Seminar – 20 Jan 2015

18. • British Influence @britinfluence Sep 18 @ProAxsis Congratulations
on securing an EU SME Instrument grant!
http://bit.ly/1o5aEiM http://bit.ly/UuYHtQ
• Stratified Medicine retweeted a Tweet you were mentioned in
Sep 22: @EU_Commission announce @ProAxsis secured an EU
SME Instrument #grant! Sending our congrats!
http://bit.ly/1o5aEiM http://bit.ly/UuYHtQ
• Sep 23: Congratulations to Dr Lorraine Martin @QUBPharmacy on
being among the first to receive a EU SME Instrument grant.
• H2020 SME Instrument @H2020SME Oct 16 #H2020
#SMEinstrument project: ENABLE Neutrophil elastase activity home
test for better treatment of lung exacerbations by @ProAxsis, UK
• MRC Impact @MRCeVal Nov 14 New @MRCcomms spin outs inc
@ProAxsis from @QueensUBelfast voted one of NI promising tech
companies http://bit.ly/1xWRZLI #researchfish
• H2020 SME Instrument @H2020SME Dec 4 #H2020
#SMEinstrument project: ENABLE Neutrophil elastase activity home
test for better treatment of lung exacerbations by @ProAxsis UK

19. Tangible benefits & PR
 Horizon 2020 SME Instrument
 €50K lump sum to support the building of resources for the
preparation of Phase 2; no detailed financial accounting
 Familiarity with the portal and process, prior to submission of
larger phase 2
 PR and company exposure
 Press releases
 Twitter
 Linkedin contacts
 Potential opportunities for collaboration
Fast Track to Innovation Seminar – 20 Jan 2015

20. On the Horizon
 Horizon 2020 SME Instrument
 Completion of Phase 1 deliverable
 Clinical validation & regulatory
approval of PoC test
 Phase 2 preparation & submission
Fast Track to Innovation Seminar – 20 Jan 2015

21. CONTACT
Dr Lorraine Martin
ProAxsis Ltd
63 University Road
Belfast BT7 1NF
Phone: +44 (0)2890 975711
Email: lorraine.martin@proaxsis.com
www.proaxsis.com
Follow on Twitter @proaxsis